| Immunology |
|
|
|
| The Immunology Group at the
NCTCC has extensive experience in the development and production of
polyclonal and monoclonal antibodies. These can be produced to native
proteins, whole cells, synthetic peptides, recombinant / fusion proteins, or
drug metabolites. The group also carries out research at the highest
international level in collaborations with academic and clinical partners.
The Immunology Group collaborates with both academic and industrial partners in the development of unique monoclonal antibodies. Monoclonal antibodies to the multidrug resistance markers MDR-1, MDR-3, Topo IIa and MRP1 have been developed at the NCTCC and are available commercially. Research Areas:
Selected Research Publications Liang Y
et al., (2001). Selection with melphalan or paclitaxel (Taxol) yields
variants with different patterns of multidrug resistance, integrin
expression and in vitro invasiveness. Eur J Cancer 37: 1041-1052. Larkin A et al., (1999). A new monoclonal antibody that specifically recognises the MDR-3-encoded gene product. Int J Cancer 80: 265-271. Moran E et al., (1998). Monoclonal antibodies raised to paraffin wax embedded archival tissue; feasibility study of their potential to detect novel antigenic markers.J Immunol Methods 219: 151-159. Moran E et al., (1997). A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. J Clin Pathol. 50: 465-471. Moran E et al., (1997). Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur J Cancer 33: 652-660.
|
|
| Staff: | AnneMarie Larkin |